摘要
目的探讨急性ST段抬高型心肌梗死(STEMI)患者急诊经皮冠状动脉介入治疗(PCI)术前早期、强化给予阿托伐他汀对对比剂肾病(CIN)的预防作用。方法选择行急诊PCI的STEMI患者120例,随机分为常规他汀治疗组(对照组,n=60)和强化他汀治疗组(研究组,n=60)。两组患者分别于急诊PCI术前开始口服阿托伐他汀20mg/d或60mg/d,连续使用7d,之后以20mg/d维持治疗。观察两组患者术前、术后1、2、3、5、7d血清肌酐(Scr)、估算肾小球滤过率(eGFR)变化情况。CIN定义为:使用对比剂后3d内SCr较基础水平升高≥25%,或绝对值升高≥0.5mg/dl。结果 (1)对照组与研究组Scr、eGFR水平在术前、术后各时间点之间比较均无统计学差异(P>0.05)。两组Scr均在PCI术后第2天较术前升高(P<0.05),第3天达峰值,第7天降至正常。两组eGFR在PCI术后第1天均较术前降低(P<0.05),第2天达谷值;研究组eGFR在第5天恢复至正常,而对照组在第7天恢复至正常。(2)对照组和研究组CIN发生率之间比较无统计学差异(6.7%vs.3.3%,P=0.675)。亚组分析显示,基础肾功能正常的患者无CIN发生;对照组和研究组基础肾功能不全的患者CIN发病率分别为23.5%和10%,但二者比较无统计学差异(P=0.383)。结论对于STEMI患者,在标准水化治疗的基础上,急诊PCI术前短期、强化给予阿托伐他汀可能不能降低CIN的发生风险。
Objective To evaluate whether short-term high-dose atorvastatin administered before emergency percutaneous coronary intervention (PCI) could reduce the incidence of contrast-induced nephropathy (CIN) in patients with acute ST-segment elevation myocardial infarction (STEMI).Methods 120 patients with STEMI undergoing emergency PCI randomly received either atorvastatin 60 mg (study group,n =60) or 20 mg (control group,n =60) before and 7 days after intervention.All patients had long-term atorvastatin treatment thereafter (20mg/d).Serum creatinine (Scr) levels and estimated glomerular filtration rate (eGFR) were measured before and at 1,2,3,5 and7 d after PCI.CIN was defined as an increase in the Scr values of ≥25% or ≥0.5 mg/dl from the baseline within 3 days after PCI.Results (1) There were no significant differences in the levels of Scr and eGFR between the two groups at all time points (P > 0.05).The level of Scr in the two groups significantly increased 2 days after PCI (P < 0.05) ; Scr peaked 3 days after PCI,and decreased to the baseline level 7 days after PCI.The level of eGFR in the two groups significantly decreased 1 day after PCI (P < 0.05) and eGFR fell to its lowest level 2 days after PCI.eGFR increased to the baseline level 5 days after PCI in the study group and 7 days after PCI in the control group.(2)There was no significant difference in the incidence of CIN between the control group and study group (6.7% vs.3.3%,P =0.675).In a subgroup analysis,there was no CIN occurred in patients with normal renal function.In the patients with pre-existing renal insufficiency,23.5% of those in the study group developed CIN versus 10.0% of those in the control group (P =0.383).Conclusions A short-term administration of high doses of atorvastatin before contrast exposure,in addition to standard intravenous hydration,may not be able to decrease CIN occurrence in patients with acute STEMI undergoing emergency PCI.
出处
《中华临床医师杂志(电子版)》
CAS
2013年第3期34-37,共4页
Chinese Journal of Clinicians(Electronic Edition)
基金
广东省科技厅项目(2010B080702010)
关键词
血管成形术
经腔
经皮冠状动脉
他汀类药物
对比剂肾病
预防
Percutaneous transluminal coronary angioplasty
Statins
Contrast-induced nephropathy
Prevention